Health Care [ 3/12 ] | Biotechnology [ 26/74 ]
NASDAQ | Common Stock
Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases.
It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.
The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113.
Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 4, 24 | -0.54 Increased by +6.90% | -0.60 Increased by +10.00% |
| Aug 6, 24 | -0.50 Increased by +26.47% | -0.60 Increased by +16.67% |
| May 7, 24 | 3.26 Increased by +586.57% | 1.19 Increased by +173.95% |
| Feb 27, 24 | 0.44 Increased by +163.77% | -0.03 Increased by +1.57 K% |
| Nov 2, 23 | -0.58 Increased by +9.38% | -0.69 Increased by +15.94% |
| Aug 3, 23 | -0.68 Increased by +19.05% | -0.65 Decreased by -4.62% |
| May 4, 23 | -0.67 Decreased by -55.81% | -0.73 Increased by +8.22% |
| Mar 15, 23 | -0.69 Increased by +10.39% | -0.64 Decreased by -7.81% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 4.67 M Increased by +N/A% | -33.21 M Increased by +2.62% | Decreased by -710.37% Decreased by N/A% |
| Jun 30, 24 | 4.17 M Increased by +N/A% | -30.62 M Increased by +20.40% | Decreased by -734.73% Decreased by N/A% |
| Mar 31, 24 | 254.95 M Increased by +N/A% | 207.34 M Increased by +759.71% | Increased by +81.32% Decreased by N/A% |
| Dec 31, 23 | 60.00 M Increased by +N/A% | 27.34 M Increased by +187.37% | Increased by +45.56% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -34.10 M Decreased by -13.08% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by -100.00% | -38.46 M Increased by +5.34% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by -100.00% | -31.43 M Decreased by -51.47% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by -100.00% | -31.29 M Increased by +15.23% | Decreased by N/A% Decreased by N/A% |